Canopy Growth Corp
TSX:WEED
Canopy Growth Corp
Canopy Growth Corp. engages in the production and sale of medical cannabis. The company is headquartered in Smiths Falls, Ontario and currently employs 3,259 full-time employees. The company went IPO on 2010-06-04. The firm operates through two segments: Global Cannabis and Other Consumer Products. The Global Cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Other Consumer Products segment comprises the production, distribution and sale of consumer products, including Storz & Bickel vaporizers; This Works beauty, skincare, wellness and sleep products; BioSteel sports nutrition beverages, mixes, protein, gum and mints; and other revenue sources.
Canopy Growth Corp. engages in the production and sale of medical cannabis. The company is headquartered in Smiths Falls, Ontario and currently employs 3,259 full-time employees. The company went IPO on 2010-06-04. The firm operates through two segments: Global Cannabis and Other Consumer Products. The Global Cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Other Consumer Products segment comprises the production, distribution and sale of consumer products, including Storz & Bickel vaporizers; This Works beauty, skincare, wellness and sleep products; BioSteel sports nutrition beverages, mixes, protein, gum and mints; and other revenue sources.
Balance Sheet Strength: Canopy ended the quarter with $371 million in cash and a net cash position of $146 million, its strongest since fiscal 2022. Post-quarter recapitalization further improved liquidity and extended debt maturities to 2031.
Canadian Cannabis Growth: Canadian medical cannabis net revenue grew 15% year-over-year, marking the sixth consecutive quarter of growth. Canadian adult-use cannabis revenue rose 8% year-over-year.
Storz & Bickel Surge: Storz & Bickel net revenue jumped 45% sequentially, driven by seasonal sales and the new VEAZY device.
Cost Savings: The company identified $29 million in annualized savings, exceeding initial expectations, and reported its slimmest adjusted EBITDA loss to date at $3 million.
MTL Cannabis Acquisition: Canopy expects its proposed MTL Cannabis acquisition to be accretive to revenue, gross margin, and EBITDA, strengthening its position in key markets.
International Expansion: International cannabis sales increased 22% quarter-over-quarter, with plans to further unlock growth in Europe as supply chain and product portfolio expand.
Guidance: Management reiterated its target to achieve positive adjusted EBITDA during fiscal 2027, supported by improving margins and continued cost discipline.
